Ozempic cost without insurance is the most common reason people either cannot start or choose to stop GLP-1 therapy. With a list price exceeding $1,000 per month, the medication sits far out of reach without assistance for many patients. But there are more options than most people know about, and the pricing landscape is changing significantly in 2027.
This guide covers the actual current prices, every available savings mechanism, and what to expect as the market shifts.
What Ozempic Actually Costs Without Insurance in 2026
The retail list price of Ozempic (semaglutide injection) is approximately $1,027 per month across all available doses (0.5 mg, 1 mg, and 2 mg) as of mid-2026.
Wegovy, the same drug at the higher 2.4 mg dose approved specifically for obesity management, lists at approximately $1,349 per month.
Rybelsus, the oral semaglutide tablet, lists at approximately $1,027 per month.
These are list prices, which is what someone pays with no savings program, no insurance, and no coupon. Very few people actually pay the full list price.
The Novo Nordisk Self-Pay Program
In November 2025, Novo Nordisk launched a direct self-pay pricing program that is significantly lower than the list price and does not require insurance.
Under this program:
- First two months: $199 per month for any Ozempic or Wegovy dose
- After two months: $349 per month for most doses; $499 per month for Ozempic 2 mg
This program is specifically for self-pay patients. Patients using insurance cannot participate. Eligibility is verified at purchase. This pricing is available through Novo Nordisk’s direct channel and participating pharmacies.
For patients starting fresh, the $199 introductory rate covers the two lowest dose levels of the standard titration schedule, which is the period where efficacy needs the most time to establish.
The January 2027 Price Cut: What to Know
In 2026, Novo Nordisk announced it will reduce list prices for all semaglutide products to $675 per month effective January 1, 2027. This represents:
- A 34 percent reduction from Ozempic’s current list price (~$1,027 to $675)
- A 50 percent reduction from Wegovy’s current list price (~$1,349 to $675)
The $675 price applies uniformly across doses and product lines. This is the list price, not the effective price after savings programs or insurance negotiations, which means real out-of-pocket costs will likely be lower still for most patients.
However, analysts note that the reduction in list price may not translate directly to reduced costs for employer-sponsored insurance plans, because insurer negotiations, rebates, and pharmacy benefit manager structures affect net pricing independently. Patients paying out of pocket will see the clearest benefit.
Insurance Coverage: What It Covers and What It Does Not
Type 2 diabetes indication: Ozempic prescribed for type 2 diabetes is covered by most commercial insurance plans, though copays and formulary placement vary. The standard copay with insurance and the NovoCare savings card can be reduced to as low as $25 per month for eligible commercially insured patients.
Obesity indication (Wegovy): Coverage for Wegovy is less consistent. Many commercial plans now include obesity medication coverage, but employer decisions drive this more than insurer policy. Medicare Part D began covering certain GLP-1 medications for obesity in 2025, specifically for patients with established cardiovascular disease, following the SELECT trial results.
Off-label prescribing: Ozempic prescribed off-label for weight loss (without a diabetes diagnosis) is typically not covered by insurance. The on-label weight loss version is Wegovy.
The NovoCare Savings Card
For commercially insured patients, Novo Nordisk’s NovoCare savings card can reduce the copay to as low as $25 per month, covering up to $100 in monthly savings for up to 48 months.
This applies only to patients with commercial insurance. Medicare and Medicaid patients are not eligible for manufacturer savings cards under federal regulations.
To use the card: obtain it from the NovoCare website (novocare.com), present it at the pharmacy along with your insurance card, and the copay reduction applies at point of sale.
The Novo Nordisk Patient Assistance Program
For uninsured or underinsured patients who cannot afford the medication, Novo Nordisk’s Patient Assistance Program provides Ozempic at no cost to eligible patients. Income limits and other eligibility criteria apply. Applications are submitted through Novo Nordisk’s assistance program and require physician participation.
This program can bridge access for patients who fall into the coverage gap: too much income to qualify for Medicaid but not enough to absorb monthly costs of $1,000+.
GoodRx and Third-Party Coupons
GoodRx and similar discount pharmacy programs can reduce the out-of-pocket cost to approximately $900 to $1,000 per month for Ozempic, slightly below the list price. The savings are less dramatic than the manufacturer’s self-pay program, making GoodRx most useful for patients who cannot access the Novo Nordisk program directly.
GoodRx coupons cannot be combined with insurance or manufacturer savings programs. You use one or the other.
Compounded Semaglutide: Lower Cost, Higher Uncertainty
Compounded semaglutide from telehealth pharmacies typically costs $150 to $400 per month, significantly below any brand-name option.
The trade-offs are real and should be understood before choosing this route.
| Factor | Brand-Name Ozempic | Compounded Semaglutide |
|---|---|---|
| Price per month | $349+ (self-pay program) | $150 to $400 |
| FDA oversight | Full (NDA approved) | Limited (503A/503B compounding) |
| Dose accuracy | Certified to label | Varies by pharmacy batch |
| Regulatory status | Stable | Evolving; enforcement ongoing |
| Availability | Nationwide | Varies by state and pharmacy |
The FDA declared Ozempic and Wegovy no longer in shortage in late 2024, which narrowed the legal basis for compounding these drugs. The agency has taken enforcement action against some compounding pharmacies. The legal and quality landscape for compounded semaglutide continues to evolve as of mid-2026.
Patients choosing compounded semaglutide should verify the pharmacy’s accreditation, ensure the physician providing oversight is licensed in their state, and discuss the regulatory context with their healthcare provider.
When Will Ozempic Have a Generic?
Semaglutide’s core composition-of-matter patents are expected to expire around 2031 to 2032. After expiration, generic injectable semaglutide could enter the market, which would significantly reduce costs. The exact timeline depends on patent challenges, regulatory approval processes, and Novo Nordisk’s strategies to extend exclusivity.
There is no approved generic semaglutide available as of mid-2026.
The Best Approach Based on Your Situation
| Patient Situation | Best Option |
|---|---|
| Commercially insured, T2D diagnosis | Insurance + NovoCare card ($25/month copay) |
| Self-pay, starting treatment now | Novo Nordisk $199/$349 self-pay program |
| Uninsured, low income | NovoCare Patient Assistance Program (free) |
| Self-pay, willing to use telehealth | Compounded semaglutide ($150-400/month) with verified pharmacy |
| All patients starting Jan 2027 | List price drops to $675 across all options |
| Waiting for maximum savings | Generic expected approximately 2031-2032 |
The cost situation for semaglutide is improving faster than for most specialty medications. The January 2027 price cut and the active patient assistance programs mean that the effective out-of-pocket cost for many patients is substantially lower than the headline list price suggests.